Expression of neddylation-related proteins in melanoma cell lines and the effect of neddylation on melanoma proliferation

Oncology Letters

Volumn 7, Issue 5, 2014, Pages 1645-1650

  Cheng, Fang ^a   He, Runzhi ^b   Zhang, Lei ^c   Li, Hui ^b   Zhang, Wei ^d   Ji, Xiaolin ^b   Kong, Fanting ^b   Sun, Jianfang ^d   Chen, Shubo ^b  

^a Department of Dermatology ^*  (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c Cancer Hospital of Jiangxi Province   (China)

^d INSTITUTE OF DERMATOLOGY   (China)

Author keywords

Apoptosis; Cell cycle; Melanoma; Neddylation; Ubiquitination

Indexed keywords

BORTEZOMIB; CYCLIN D; NEDD8 PROTEIN; SCAFFOLD PROTEIN; SMALL INTERFERING RNA;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL PROLIFERATION; CLINICAL ARTICLE; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; MELANOMA; MIDDLE AGED; NEDDYLATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; RNA INTERFERENCE; UBIQUITINATION; UPREGULATION; VERY ELDERLY; WESTERN BLOTTING;

EID: 84896381855     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.1953     Document Type: Article

References (27)

1. Chen RH, Lee YR and Yuan WC: The role of PML ubiquitination in human malignancies. J Biomed Sci 19: 81, 2012.
2. Duncan K, Schäfer G, Vava A, Parker MI and Zerbini LF: Targeting neddylation in cancer therapy. Future Oncol 8: 1461-1470, 2012.
3. Hjerpe R and Rodríguez MS: Alternative UPS drug targets upstream the 26S proteasome. Int J Biochem Cell Biol 40: 1126-1140, 2008.
4. Tsvetkov P, Reuven N and Shaul Y: Ubiquitin-independent p53 proteasomal degradation. Cell Death Differ 17: 103-108, 2010.
5. Allende-Vega N and Saville MK: Targeting the ubiquitin-proteasome system to activate wild-type p53 for cancer therapy. Semin Cancer Biol 20: 29-39, 2010.
6. Yu ZK, Gervais JL and Zhang H: Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21 (CIP1/WAF1) and cyclin D proteins. Proc Natl Acad Sci USA 95: 11324-11329, 1998.
7. Dace A, Zhao L, Park KS, et al: Hormone binding induces rapid proteasome-mediated degradation of thyroid hormone receptors. Proc Natl Acad Sci USA 97: 8985-8990, 2000.
8. Wada H, Yeh ET and Kamitani T: A dominant-negative UBC12 mutant sequesters NEDD8 and inhibits NEDD8 conjugation in vivo. J Biol Chem 275: 17008-17015, 2000.
9. Rabut G and Peter M: Function and regulation of protein neddylation. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep 9: 969-976, 2008.
10. Wu K, Chen A and Pan ZQ: Conjugation of Nedd8 to CUL1 enhances the ability of the ROC1-CUL1 complex to promote ubiquitin polymerization. J Biol Chem 275: 32317-32324, 2000.
11. Hoeller D and Dikic I: Targeting the ubiquitin system in cancer therapy. Nature 458: 438-444, 2009.
12. Bergink S and Jentsch S: Principles of ubiquitin and SUMO modifications in DNA repair. Nature 458: 461-467, 2009.
13. Paoluzzi L and O'Connor OA: Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas. BioDrugs 20: 13-23, 2006.
14. O'Connor OA: Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma. Clin Lymphoma Myeloma 6: 191-199, 2005.
15. Yang Y, Kitagaki J, Dai RM, et al: Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res 67: 9472-9481, 2007.
16. Soucy TA, Smith PG and Rolfe M: Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res 15: 3912-3916, 2009.
17. Chairatvit K and Ngamkitidechakul C: Control of cell proliferation via elevated NEDD8 conjugation in oral squamous cell carcinoma. Mol Cell Biochem 306: 163-169, 2007.
18. Cheng F, Chen H, Zhang L, Li RH, Liu Y and Sun JF: Inhibition of the NEDD8 conjugation pathway by shRNA to UBA3, the subunit of the NEDD8-activating enzyme, suppresses the growth of melanoma cells. Asian Pac J Cancer Prev 13: 57-62, 2012.
19. Soucy TA, Smith PG, Milhollen MA, et al: An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458: 732-736, 2009.
20. Gong L, Kamitani T, Millas S and Yeh ET: Identification of a novel isopeptidase with dual specificity for ubiquitin- and NEDD8-conjugated proteins. J Biol Chem 275: 14212-14216, 2000.
21. Hemelaar J, Borodovsky A, Kessler BM, et al: Specific and covalent targeting of conjugating and deconjugating enzymes of ubiquitin-like proteins. Mol Cell Biol 24: 84-95, 2004.
22. Coupland SE, Bechrakis N, Schüler A, Anagnostopoulos I, Hummel M, Bornfeld N and Stein H: Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma. Br J Ophthalmol 82: 961-970, 1998.
23. Abukhdeir AM and Park BH: P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med 10: e19, 2008.
24. Gartel AL and Tyner AL: The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1: 639-649, 2002.
25. Finucane DM, Bossy-Wetzel E, Waterhouse NJ, Cotter TG and Green DR: Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL. J Biol Chem 274: 2225-2233, 1999.
26. Xirodimas DP and Scheffner M: Ubiquitin family members in the regulation of the tumor suppressor p53. Subcell Biochem 54: 116-135, 2010.
27. Zuo J, Bi C, Fan Y, Buac D, Nardon C, Daniel KG and Dou QP: Cellular and computational studies of proteasome inhibition and apoptosis induction in human cancer cells by amino acid Schiff base-copper complexes. J Inorg Biochem 118: 83-93, 2013.